Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 2/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
| ▸ | TAS2R14 | Q9NYV8 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 4/20 | 0.41 |
| ▸ | PPARA | Q07869 | 3/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | VNN1 | O95497 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14860346 | 0.86 | MAOB (0.33) | RIPK1TAS2R14MAOB | |
| SCHEMBL16673886 | 0.85 | HTR2A (0.49) | MEN1KMT2APPARGPPARAOPRM1 | |
| SCHEMBL4902032 | 0.85 | HTR2A (0.49) | MEN1KMT2APPARGPPARAOPRM1 | |
| SCHEMBL16673885 | 0.85 | HTR2A (0.49) | MEN1KMT2APPARGPPARAOPRM1 | |
| SCHEMBL5066181 | 0.84 | ALPI (0.43) | RIPK1MEN1KMT2AOPRM1OPRD1 | |
| SCHEMBL18344466 | 0.84 | ALPI (0.43) | RIPK1MEN1KMT2AOPRM1OPRD1 | |
| SCHEMBL4064873 | 0.84 | ALPI (0.43) | RIPK1MEN1KMT2AOPRM1OPRD1 | |
| SCHEMBL14860492 | 0.84 | CTSB (0.38) | MEN1KMT2ACTSSOPRM1OPRD1 | |
| SCHEMBL14860505 | 0.84 | PTGES (0.44) | RIPK1MEN1KMT2ACTSSCTSK | |
| SCHEMBL674473 | 0.81 | KMT2A (0.46) | SLC1A1RIPK1TAS2R14MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895571-B2 | Isoindolinone and pyrrolopyridinone derivatives as Akt inhibitors | INCYTE CORPORATION (US) | 2014-11-25 | — | — | US | disclosed |
| US-20130096144-A1 | ISOINDOLINONE AND PYRROLOPYRIDINONE DERIVATIVES AS AKT INHIBITORS | INCYTE CORPORATION (US) | 2013-04-18 | — | — | US | disclosed |
| US-20110160255-A1 | INHIBITORS OF AKT ACTIVITY | GLAXOSMITHKLINE LLC | 2011-06-30 | — | — | US | disclosed |
| US-20110160256-A1 | INHIBITORS OF AKT ACTIVITY | GLAXOSMITHKLINE LLC | 2011-06-30 | — | — | US | disclosed |
| US-20110129455-A1 | INHIBITORS OF AKT ACTIVITY | GLAXOSMITHKLINE LLC | 2011-06-02 | — | — | US | disclosed |
| US-20110098221-A1 | INHIBITORS OF Akt ACTIVITY | GLAXOSMITHKLINE LLC | 2011-04-28 | — | — | US | disclosed |
| US-20110092423-A1 | INHIBITORS OF Akt ACTIVITY | GlaxoSmithKline, LLC | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160256-A1 | INHIBITORS OF AKT ACTIVITY | AKT2, AKT1, PIK3CA | SLC1A1 3594/4885RIPK1 211/4885TAS2R14 4741/4885 |
| US-20110092423-A1 | INHIBITORS OF Akt ACTIVITY | AKT2, AKT1, PIK3CA | SLC1A1 3594/4885RIPK1 211/4885TAS2R14 4741/4885 |
| US-20130096144-A1 | ISOINDOLINONE AND PYRROLOPYRIDINONE DERIVATIVES AS AKT INHIBITORS | MTOR, PDPK1, PIK3CA | SLC1A1 3019/4885RIPK1 185/4885TAS2R14 4557/4885 |
| US-20110160255-A1 | INHIBITORS OF AKT ACTIVITY | AKT2, AKT1, PIK3CA | SLC1A1 3594/4885RIPK1 211/4885TAS2R14 4741/4885 |
| US-20110129455-A1 | INHIBITORS OF AKT ACTIVITY | AKT2, AKT1, PI4KB | SLC1A1 3588/4885RIPK1 191/4885TAS2R14 4684/4885 |
| US-20110098221-A1 | INHIBITORS OF Akt ACTIVITY | AKT2, AKT1, PIK3CA | SLC1A1 3594/4885RIPK1 211/4885TAS2R14 4741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.